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ABSTRACT
Anthracyclines are among the most active drugs in
breast cancer. Because of excessive cardiotoxicity,
their use in combination with trastuzumab has been
discouraged in patients with human epidermal
growth factor receptor (HER)-2
 metastatic breast
cancer. We sought to describe how this treatment
paradigm influenced the use of anthracyclines in this
patient setting.
We analyzed a multi-institutional database contain-
ingthetreatmenthistoryof450patientswhoreceivedat
least one trastuzumab-based regimen for HER-2
 met-
astatic breast cancer. Patients were considered eligible
for anthracyclines for metastatic disease if they were
never exposed (NE) or had been previously exposed
(PE)toananthracyclineintheneoadjuvantoradjuvant
setting and had relapsed after 12 months from the last
dose. We then assessed the use of anthracycline-based
therapy after failure with the first trastuzumab-based
regimen in eligible patients.
Three-hundred twenty-one patients were considered
eligible for anthracyclines. In total, 190 eligible patients
developingdiseaseprogressionduringtheinitialtrastu-
zumab-based therapy were analyzed. An anthracycline
was administered as first salvage treatment in 14 NE
and two PE patients. Another 15 NE and nine PE pa-
tientsreceivedananthracyclineasafurtherlineofther-
apy. Of 119 eligible patients who died from breast
cancer,only30receivedananthracyclineformetastatic
disease.
In conclusion, despite the fact that two thirds of the
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HER-2 metastatic breast cancer are eligible for an-
thracyclines, these drugs are infrequently used now-
adays to treat trastuzumab-refractory disease. A role
for these compounds should be redefined in this pa-
tient subset. The Oncologist 2010;15:665–672
INTRODUCTION
Anthracyclines have been the mainstay of the treatment of
metastatic breast cancer for the last three decades. Clinical
trials in the adjuvant setting have demonstrated that anthra-
cycline-based combinations yield superior outcomes
compared with cyclophosphamide, methotrexate, and
5-fluorouracil–like regimens [1]. A recent meta-analysis of
three randomized studies in metastatic breast cancer pa-
tients showed that the antitumor activity of single-agent
doxorubicin is comparable with that of single-agent tax-
anes, which are now considered the first-line agents of
choice [2]. Previous exposure to neoadjuvant or adjuvant
anthracyclines does not preclude meaningful rates of tumor
control when patients with features of potential sensitivity
(i.e., metastatic progression occurring beyond 12 months
from the completion of adjuvant anthracycline-based ther-
apy)arerechallengedwiththesedrugs[3].Asteepincrease
in the risk for irreversible cardiotoxicity for cumulative
doses of doxorubicin and epidoxorubicin 550 mg/m
2 and
1,000mg/m
2,respectively,representsthemainlimitation
to rechallenge with these drugs [4, 5]. Liposome-encapsu-
lated doxorubicins, which are much less cardiotoxic than
the traditional compound, can be safely administered to
previously exposed patients, allowing higher cumulative
doses [6–8].
A high rate of clinical cardiotoxicity was observed with
the combination of doxorubicin and the monoclonal anti-
body trastuzumab in a pivotal randomized trial conducted
in patients with human epidermal growth factor receptor
(HER)-2
 advanced breast cancer [9]. The overall results
of that trial and of another randomized phase II study [10]
showed that the addition of trastuzumab to chemotherapy
resulted in a dramatic improvement in the prognosis of
these patients. Based on these results, the upfront use of
trastuzumabwithnonanthracyclinechemotherapyandcon-
tinuous HER-2 targeting with trastuzumab or newer anti–
HER-2 compounds when tumor progression occurs have
become solid treatment paradigms [11–13]. As a conse-
quence, a reduction in the use of anthracyclines for the
treatmentofadvancedHER-2
breastcancerisexpectedto
have occurred since the adoption of trastuzumab in clinical
practice. Interestingly, preclinical data suggest that, for a
proportion of patients with HER-2
 breast cancer, anthra-
cyclines may act as “biologically targeted therapy.” Ge-
netic alterations in the topoisomerase II gene (TOP2A)
(amplification or deletions), which are found in 40% of
HER-2–amplifiedtumorsandarevirtuallyabsentintumors
with normal HER-2 gene status, confer sensitivity to an-
thracyclines [14]. Indeed, in the pivotal trial by Slamon et
al. [9], the anthracycline-based control arm yielded a 42%
overall response rate, a median progression-free survival
interval of 6.1 months, and an overall survival duration of
21 months. These results suggest that anthracycline-based
chemotherapymaystillrepresentavaluabletherapeuticop-
tion in HER-2
 metastatic breast cancer patients whose
disease is resistant to anti–HER-2 therapy.
On these premises, we sought to quantify the use of an-
thracyclines in patients with HER-2
 advanced breast can-
cer receiving trastuzumab-based therapy between
September 1999 and November 2008. This time interval
started approximately when trastuzumab became available
in some European countries, including Italy. In the context
of the current controversy around the role of anthracyclines
in the treatment of early breast cancer [15], our analysis
provides a framework for possible strategies to reintegrate
these active agents in the management of patients with
HER-2
 advanced breast cancer.
PATIENTS AND METHODS
Patients for this analysis were selected from a multi-insti-
tutional database containing clinical data from women with
HER-2
 breast cancer receiving trastuzumab-based ther-
apy for metastatic disease. For each patient, we collected
clinical and pathological characteristics, prior treatments
for breast cancer, and details of the first trastuzumab-based
treatment and of subsequent lines of treatment until death
(drugs and doses, best tumor response according to the
World Health Organization criteria as assessed by investi-
gators at each site, date of further progression, and date of
death or of last follow-up visit). As of August 31, 2009, the
databasecontainedclinicaldatafrom450patients.Eligibil-
ity to receive anthracyclines in the metastatic setting was
retrospectivelyascertainedforeachpatientandwasdefined
as follows: (a) no exposure to these drugs in the neoadju-
vant or adjuvant setting, (b) no exposure to anthracyclines
as treatment for metastatic disease prior to or with the first-
trastuzumab-based treatment, and (c) prior exposure to an
anthracycline in the neoadjuvant or adjuvant setting and
metastatic progression occurring beyond 12 months from
treatment completion. This latter definition did not include
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ability of liposome encapsulated doxorubicin, the cumula-
tive dose of anthracyclines could no longer be considered a
contraindication to rechallenge [8]. An ad hoc analysis fo-
cused on a subset of patients treated with trastuzumab-
based therapy at two institutions (European Institute of
Oncology, Milan, Italy and Institute for Cancer Research
and Treatment, Candiolo, Italy) for whom we could collect
additionaldetailedinformationonthedosesofprioranthra-
cycline exposure. For these patients, we applied a more
stringent definition of eligibility [16]: cumulative dose
300 mg/m
2 of doxorubicin or 720 mg/m
2 of epidoxo-
rubicin and the development of metastatic disease beyond
12monthsfromthelastdoseofadjuvantchemotherapy.Pa-
tients developing clinically significant cardiac dysfunction
during trastuzumab-based therapy were considered no
longer eligible for anthracyclines.
Being a retrospective analysis, no specific written in-
formed consent was required for this study. However, the
process of data collection was conducted in compliance
withtheethicalrequirementsofeachoftheparticipatingin-
stitutions.
Statistical Analysis
Descriptive statistics are reported using the median (range)
or frequency (adjusted Wald 95% confidence interval [CI])
whereappropriate.Proportionswerecomparedusingthe
2
testandtrendsinproportionsovertimewereanalyzedusing
the 
2 test for trends (Armitage test). Univariate and multi-
variate logistic regression models were fitted to the data in
order to analyze factors associated with the use of anthra-
cyclinesinpatientsdevelopingdiseaseprogressionafterthe
initial trastuzumab-based regimen. Results are reported
with odds ratios (ORs) and 95% CIs. p-values  .05 were
considered statistically significant. Analyses were per-
formed using SPSS version 17.0 (SPSS Inc., Chicago, IL).
RESULTS
The process of patient selection for this analysis is repre-
sented in Figure 1. The demographic characteristics of the
450 patients registered in the database are summarized in
Table 1. In total, 321 patients (171 with no prior exposure
and 150 exposed only in the neoadjuvant or adjuvant set-
ting), representing 71% (95% CI, 67%–75%) of the total,
were deemed to be eligible for anthracyclines for the treat-
ment of metastatic disease (Fig. 1). Percentages of patients
in each category of eligibility or noneligibility for anthra-
cyclines in the metastatic setting before the first trastu-
zumab-based treatment were calculated by year of first
diagnosis of metastatic disease (Fig. 2). The use of anthra-
cyclinesbeforetrastuzumabastreatmentformetastaticdis-
easedeclinedsharplyforpatientsdiagnosedwithmetastatic
disease in the year 2000 and onward, with no patients
treatedintheyears2006–2008(
2testfortrendsinpropor-
tions, p  .01). The proportion of patients receiving an an-
thracycline in the adjuvant setting and found to be eligible
forretreatmentincreasedsignificantlyoverthetimeperiods
analyzed (
2 test for trends in proportions, p  .01).
Asexpected,thefirsttrastuzumab-basedtherapydidnot
include an anthracycline in most of the patients (Table 2).
Overall, at the time of data cutoff, 365 patients had experi-
enced disease progression during the initial trastuzumab-
based treatment and 254 had died. Considering the initial
criteria for retreatment and excluding 14 patients who re-
ceived trastuzumab combined with an anthracycline and
another 11 patients developing cardiotoxicity requiring
trastuzumab discontinuation, the number of patients poten-
tially eligible for anthracyclines after the initial trastu-
zumab-based regimen was 229. Twenty-three of these
patientscouldreceiveonlysupportivecarebecauseofrapid
disease progression and death. For another 16 patients, we
could not retrieve information on additional anticancer
treatment received after the initial trastuzumab-based ther-
apy. In total, 190 patients, 94 of whom had no prior expo-
Figure 1. Flow chart of the selection patients for the main
analysis.
Abbreviation: HER-2, human epidermal growth factor re-
ceptor 2.
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neoadjuvant or adjuvant setting, could be analyzed for sub-
sequenttreatmentsafterprogression.Only16(8%;95%CI,
5%–13%) of those patients received an anthracycline as
part of the first salvage treatment (Table 3). Another 24 pa-
tients(cumulativeproportion,21%;95%CI,16%–27%)re-
ceived an anthracycline-containing regimen as a further
line of therapy. Furthermore, of a total of 119 patients eli-
gible for anthracyclines who died and for whom we could
retrievecompleteinformationontreatments,only30(25%;
95% CI, 18%–34%) ever received an anthracycline for the
treatment of metastatic disease (Table 3).
Anthracycline-based therapies were heterogeneous and
includedaliposomalcompoundinabouthalfthecases.The
ad hoc analysis, including 247 patients treated at two insti-
tutions for whom we could retrieve treatment details, did
not differ from the main analysis (data not shown).
Logistic regression analysis was used to study the im-
pact of the following variables on the use of anthracyclines
after the initial trastuzumab-based therapy: patient age,
which was dichotomized around its median value of 53
years; type of eligibility for anthracyclines (never exposed
versus exposed in the neoadjuvant or adjuvant setting and
having relapsed beyond 12 months from the completion of
therapy); continuation of trastuzumab beyond the initial
trastuzumab-based regimen (versus no continuation); insti-
tution; and year of initial trastuzumab-based treatment
(1999–2001 versus 2002–2003 versus 2004–2005 versus
2006–2008). Because of the heterogeneous number of pa-
tientrecordsprovidedbyeachparticipant(seeAppendix1),
the variable “institution” was recoded into four groups,
keeping separate the three institutions providing 60 pa-
tientrecordsandcombiningalltheremainingrecordsintoa
single group.
In the 190 patients progressing during the initial trastu-
zumab-based regimen, having received prior anthracy-
clines in the neoadjuvant or adjuvant setting (OR, 0.272;
95%CI,0.124–0.596;p.01)andcontinuousadministra-
tion of trastuzumab beyond disease progression (OR,
0.360; 95% CI, 0.171–0.759; p  .01) were significantly
associated with a lower probability of receiving an anthra-
cycline. The same results were obtained when restricting
the analysis to the 119 patients who died from progressive
breast cancer (not shown).
DISCUSSION
Our study shows that, despite the fact that two thirds of the
patients receiving trastuzumab-based therapy for HER-2

metastatic breast cancer are eligible for anthracyclines,
these drugs are infrequently used to treat trastuzumab-
refractory disease nowadays. The administration of anthra-
Table 1. Patient characteristics
Variable
Value (%)
(n  450)
Median age, yrs (range) 53 (27–85)
Median disease-free interval,
a mos (range) 21 (0–146)
Stage at initial diagnosis of breast cancer
b
I/II 223 (50)
III 122 (27)
IV 102 (23)
HER-2 status
IHC 3 362 (80)
IHC 2
c 68 (15)
IHC positive NOS 20 (4)
ER
 and/or PgR
 225 (50)
Received neoadjuvant/adjuvant chemotherapy 283 (63)
Prior exposure to anthracyclines 267 (59)
Prior exposure to taxanes 110 (24)
Prior lines of chemotherapy for metastatic
disease
d
0 351 (78)
1 51 (11)
2 45 (10)
Single metastatic site 160 (36)
Pattern of metastatic disease
e
Visceral (liver and lung) 301 (67)
Nonvisceral (bone and/or soft tissue
and/or effusions)
104 (23)
Bone only 44 (10)
Central nervous system metastases (with or
without other sites)
23 (5)
Year of first diagnosis of metastatic disease
2000 52 (12)
2000–2001 95 (21)
2002–2003 108 (24)
2004–2005 133 (30)
2006–2008 62 (14)
Year of first trastuzumab-based therapy
1999–2001 102 (23)
2002–2003 110 (24)
2004–2005 154 (34)
2006–2008 84 (19)
aFrom surgery to the first evidence of recurrent disease.
bThree cases had missing stage information.
cOf the 68 patients with IHC 2 tumors, 39 (57%) had
FISH-proven HER-2 gene amplification, 15 (22%) had
negative FISH results (centralized retrospective
assessment), and for the remaining 14 patients (21%)
FISH status was not available.
dThree cases had missing information on prior lines of
chemotherapy for metastatic disease.
eOne patient had missing information on pattern of
metastatic disease.
Abbreviations: ER, estrogen receptor; FISH, fluorescence
in situ hybridization; HER-2, human epidermal growth
factor receptor 2; IHC, immunohistochemistry; NOS, not
otherwise specified; PgR, progesterone receptor; T,
trastuzumab.
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trastuzumab-basedregimendeclinedsharplyaftertheintro-
duction of this monoclonal antibody in clinical practice
(Fig. 2). This trend is justified by the rapid adoption by on-
cologists of the paradigm that anthracycline-free combina-
tions of trastuzumab with chemotherapy should be
administered at the onset of HER-2
 metastatic breast can-
cer [9]. After trastuzumab failure, a minority of eligible pa-
tients received an anthracycline, either as first-salvage
treatment or at any time for further tumor progression. Use
of an anthracycline was particularly infrequent in patients
whohadbeenexposedtothesedrugsintheadjuvantsetting
(cumulative proportion, 12%). The frequency of anthracy-
cline use was higher in anthracycline-naïve patients, but in
thisgroupthemajorityalsoreceivedalternativetreatments.
In fact, about one third of the dying patients never received
an anthracycline throughout their entire disease course
(Table 3).
Before discussing the potential relevance of our find-
ings, we must point out some obvious limitations of our
analysis. The first issue is with the number of patients in-
volved: The analysis of patterns of anthracycline use was
restrictedtoonly190patientswhowereconsideredeligible
for anthracyclines, had experienced disease progression
Figure 2. Proportion of patients fulfilling each definition for eligibility or noneligibility for treatment with anthracyclines for
metastatic disease by year of diagnosis of first metastasis. Below each bar of the graph is summarized, by each time period, the
number of patients in each category of eligibility. Numbers in parentheses represent column percentages.
Table 2. Summary of initial trastuzumab-based regimens
Treatment in combination with
trastuzumab
n of
patients
a %
Docetaxel, 75–100 mg/m
2 q3wks 139 32
i.v. vinorelbine, 25–30 mg/m
2 weekly 119 28
Paclitaxel, 80/90 mg/m
2 weekly 44 10
Oral vinorelbine, 60/80 mg/m
2 weekly 30 7
Paclitaxel, 175 mg/m
2 q3wks 21 5
Docetaxel, 75 mg/m
2 q3wks 
epidoxorubicin, 75 mg/m
2 14 3
Trastuzumab alone 14 3
Paclitaxel, 80/90 mg/m
2 weekly 
carboplatin, AUC  2 weekly
13 3
Other regimens (10 patients per
regimen)
37 9
aFor 19 patients, the initial trastuzumab-based regimen
was not detailed.
Abbreviations: AUC, area under the curve; q3wks, every
3 weeks; T, trastuzumab.
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ceive additional anticancer therapy. A further analysis fo-
cused on 119 of these patients who died during the
observationperiod.Therefore,thegeneralizabilityofour
results is limited by wide CIs around the point estimates
and by restrictions in the number of potential predictors
that could be studied by multivariate analysis. Second,
this was a retrospective analysis of data initially col-
lected to test hypotheses other than the use of anthracy-
clines [17]. Third, our definition of eligibility for
anthracyclines for patients pretreated in the neoadjuvant
oradjuvantsettingcouldbecriticizedbecausewedidnot
take into account dose thresholds of prior exposure to
conventional anthracyclines. However, the ad hoc anal-
ysis, in which the dose of prior anthracyclines was in-
cluded as a criterion to establish eligibility to
rechallenge, provided similar results [16].
Most of the patients were treated in the context of the
availability of liposomal doxorubicins, which renders prior
cumulativedosesofanthracyclinesapproachingthethresh-
olds for cardiotoxicity no longer a contraindication to re-
treatment [8]. In fact, in Italy both nonpegylated and
pegylateddoxorubicinhavebeenavailableforcompassion-
ate use in breast cancer since the late 1990s and were reg-
isteredforthisindicationinmid-2001andintheearly2003,
respectively.
Despite these limitations, we believe that our analysis
providesarealisticpictureofhowthecurrentuseofanthra-
cyclines in HER-2
 metastatic breast cancer patients has
declined since the introduction of trastuzumab. This mono-
clonal antibody has caused a dramatic change in the natural
history of HER-2
 advanced breast cancer. Encouraging
results with newer compounds reinforce the concept that
continuedHER-2targetingisthebackboneoftreatmentfor
these patients [12, 13]. Indeed, the multivariate analysis
showed that the policy of continuing trastuzumab beyond
tumorprogressionwassignificantlyassociatedwithalower
probability of receiving an anthracycline. Trastuzumab-
related left ventricular ejection fraction is reversible and
Table 3. Summary of anthracycline use in patients progressing during the initial trastuzumab-based regimen
Type of eligibility
Anthracycline as first
salvage treatment
Anthracycline at
any time
n %
a (95% CI) n %
a (95% CI)
Overall
Never exposed (n  94) 14 15 (9–24) 29 31 (22–41)
Exposed in the neoadjuvant or adjuvant setting (n  96) 2 2 (0–8) 11 12 (6–20)
Total (n  190) 16 8 (5–13) 40 21 (16–27)
Dead
Never exposed (n  62) 13 21 (12–33) 21 34 (23–46)
Exposed in the neoadjuvant or adjuvant setting (n  57) 2 4 (2–17) 9 16 (7–28)
Total (n  119) 15 13 (8–20) 30 25 (18–34)
aRow percentages.
Abbreviations: CI, confidence interval.
Appendix 1. Participating institutions and relative
contribution in patient records
Institute Frequency Percent
Institute for Cancer Research and
Treatment, Candiolo, Italy
138 30.7
European Institute of Oncology,
Milano, Italy
122 27.1
Molinette Hospital, Centro
Oncologico Subalpino (COES),
Torino, Italy
64 14.2
Mauriziano Hospital, Division of
Gynecology, Torino, Italy
22 4.9
Istituto Nazionale Tumori,
Genova, Italy
18 4.0
Regional Hospital, Treviso, Italy 16 3.6
IST Fondazione Senatore
Pascale, Napoli, Italy
15 3.3
Giovanni Bosco Hospital,
Torino, Italy
12 2.7
Unit of Gynecology, S. Anna
Hospital, Torino, Italy
11 2.4
Semmelweiss University,
Budapest, Hungary
10 2.2
Royal Surrey County Hospital,
Surrey, Great Britain
9 2.0
Breast Unit, Cremona, Italy 7 1.6
Clinica Universitaria, S. Anna
Hospital, Torino, Italy
6 1.3
Total 450 100.0
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myocardialcells[18,19].Normally,thispathwayiselicited
through the expression of neuregulins when the myocar-
dium encounters adverse hemodynamic stress or other
stresses like those induced by anthracyclines. Neuregulins
arenaturalligandsofHER-3andHER-4andinducetheir
heterodimerization with HER-2 [20]. Interference with
this relevant cell survival and growth-promoting path-
way sensitizes myocardial cells to the irreversible toxic-
ity caused by anthracyclines. For this reason, concerns
about combinations of anthracyclines and trastuzumab
have been translated to other anti–HER-2 compounds,
whichareusuallystudiedinthecontextofanthracycline-
free regimens.
The multivariate analysis also revealed that patients
exposed in the adjuvant setting and relapsing 12 months
after the last dose were less likely to receive an anthra-
cyclinedespitebeingeligibleforrechallenge.Ingeneral,
aside from concerns regarding cardiotoxicity, oncolo-
gists are reluctant to rechallenge patients with anthracy-
clines because there are limited prospective data on the
efficacy of this approach. However, a recent phase II
clinical trial with a combination of liposomal doxorubi-
cin and cyclophosphamide demonstrated a 38% overall
responserateanda71%clinicalbenefitratein70women
with advanced breast cancer previously exposed to an-
thracyclines in the adjuvant setting and relapsing beyond
12 months of the last dose [8]. These figures are compa-
rablewiththosefromotherfirst-linecombinationsinun-
selected metastatic breast cancer patients.
In recent years, the importance of anthracyclines in ad-
juvant chemotherapy regimens has been debated on the ba-
sis of the observation that HER-2 and TOP2A seem to
predicttheirefficacy[21,22].Thesefindingspointtoalim-
ited role of adjuvant anthracycline-based regimens in pa-
tients with HER-2
 breast cancer. Furthermore, a still
unpublished large clinical trial suggests that, if the anti–
HER-2 monoclonal antibody trastuzumab is part of adju-
vant treatment, anthracyclines also may be omitted in
patients with HER-2
 operable breast cancer [23]. At this
time, these results are not considered conclusive [15], but
prospective trials are ongoing that will provide potentially
practice changing findings (ClinicalTrials.gov identifier,
NCT00365365).Oneofthepossibleimplicationsisthatthe
proportion of anthracycline-naïve patients who develop
HER-2
metastaticdiseasewillincreasesignificantlyinthe
near future. Paradoxically, because of concomitant TOP2A
geneticalterations(amplificationanddeletionin40%ofthe
patients) in tumors harboring HER-2 amplification, anthra-
cyclines may be particularly active in a relevant subset of
these patients [23].
CONCLUSION
In summary, our retrospective analysis shows that anthra-
cyclines are infrequently used to treat HER-2
 advanced
breastcancer.Alternativestorechallengewithananthracy-
clineandcardiacsafetyconcernsrelatedtothecombination
of these compounds with HER-2–targeting drugs are two
plausible explanations. The activity and tolerability of the
newer less cardiotoxic liposomal anthracyclines in combi-
nation with trastuzumab are being studied, but no random-
ized comparisons with non–anthracycline-based regimens
are available [24–27]. Another possibility may arise from
a more precise definition, within the HER-2
 subset, of
factors for susceptibility or resistance to anti–HER-2
therapy [28]. In fact, despite results confirming that con-
tinuous HER-2 targeting with alternative compounds
also yields meaningful clinical activity in patients resis-
tant to a previously used anti–HER-2 compound (at this
time, mainly trastuzumab), the absolute rates of tumor
response are in the range of 5%–25% [29]. It is possible,
therefore, that despite HER-2 amplification and/or over-
expression, there may be tumors that lose or do not pos-
sess biological addiction to this oncogene. Markers of
absolute HER-2 independence, which imply refractori-
nesstoanti–HER-2therapy,regardlessoftheagentused,
may identify patients for whom anthracyclines may rep-
resent a valuable therapeutic option among those that are
currently available.
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